GMAB
GENMAB A/SPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 30 Trial readout: T-90d Trial Readout: Epcoritamab (Phase 2)
- Jul 22 ▲ TD Cowen upgrades
- Sep 15 ▲ Short interest falls 28.0% to 4.92M
- Sep 30 ▲ 3 funds open new positions (13F)
- Oct 5 ▲ Genmab and AbbVie announced positive topline Phase 3 results for epc…
- Oct 23 ▲ Genmab announced positive topline Phase 3 RAINFOL-02 results for Rin…
- Oct 26 ▲ JP Morgan upgrades
- Oct 28 ▲ Genmab announced positive topline results from the Phase 3 LiGeR-HN1…
- Oct 30 ▼ Short interest jumps 46.4% to 9.66M
Signal stack
Where each data set points today.
- InstitutionsBULLISH
Q3 2026: 35 added (3 new), 9 trimmed or exited. Largest new: Capital World Investors $139.2M.
- AnalystsBULLISH
20 of 25 rate it Buy or better. Median target $65.60 (+27%).
- Short sellersBUILDING
Short interest +46.4% to 9.66M shares. 1.2 days to cover, ≈1.6% of shares.
- TrendUPTREND
24% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 31.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $216.1M |
| Capital World Investors | NEW | $139.2M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $81.1M |
| MARSHALL WACE, LLP | ADD | $43.5M |
| UBS Group AG | TRIM | $22.5M |
| Qube Research & Technologies Ltd | TRIM | $15.2M |
| Quantinno Capital Management LP | ADD | $15.0M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $13.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
25 analystsPrice is inside the target range. Median implies +27%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Oct 30, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Oct 30, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 29, 2026 | Truist Securities REITERATE | Buy |
| Oct 29, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 26, 2026 | TD Cowen MAINTAIN | Buy |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $0.30 | $0.30–$0.31 | No data | $7.2B |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026Washington
SecBot reports
31 filings · 6 bullish · 1 bearish · 24 neutral- NEUTRAL SC 13G/ANov 16, 2026
Orbis Investment Management Ltd filed an amended Schedule 13G disclosing a reduced passive stake of 4.6% in Genmab A/S as of September 30, 2026, down from 5.9% reported in the prior filing. The decrease below the 5% threshold signals a reduction in exposure by a long-term institutional holder.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 6-KNov 12, 2026
Genmab filed a Form 6-K disclosing routine insider share sales by two board members. Board member…
These are routine insider sales by non-executive board members, not a signal of deteriorating fundamentals. Monitor upcoming quarterly results for any changes in revenue or pipeline progress.
- NEUTRAL 6-KNov 12, 2026
Genmab filed a Form 6-K disclosing a sale of 1,071 shares by Executive Vice President and Chief…
This is a routine insider trade disclosure with no material impact. Monitor for any pattern of increased insider selling in future filings, but this single transaction is immaterial relative to…
- NEUTRAL 6-KNov 12, 2026
Genmab filed its updated Articles of Association on Form 6-K, reflecting routine governance…
This is a routine filing of updated articles of association with no new financial data. Monitor future 6-K filings for earnings releases or material corporate developments.
All GMAB filing & press-release reports (31)
- SC 13G/A reportNov 16, 2026
- 6-K reportNov 12, 2026
- 6-K reportNov 12, 2026
- 6-K reportNov 12, 2026
- 6-K reportNov 12, 2026
- 6-K reportNov 10, 2026
- 144 reportNov 10, 2026
- 6-K reportNov 5, 2026
- INST-CLUSTER reportNov 4, 2026
- 6-K reportOct 28, 2026
- 6-K reportOct 23, 2026
- 6-K reportOct 13, 2026
- 6-K reportOct 7, 2026
- SC 13G reportOct 5, 2026
- 6-K reportOct 5, 2026
- 6-K reportOct 2, 2026
- 6-K reportSep 29, 2026
- 6-K reportSep 24, 2026
- 6-K reportSep 8, 2026
- 6-K reportAug 12, 2026
- 6-K reportAug 11, 2026
- 6-K reportAug 6, 2026
- 6-K reportJul 15, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 17, 2026
- 6-K reportJun 16, 2026
- 6-K reportJun 15, 2026
- 6-K reportJun 15, 2026
- 6-K reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportFeb 28, 2026